サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1365719

消化管治療薬市場：薬剤クラス別、用途別、流通チャネル別：世界の機会分析と産業予測、2023～2032年

Gastrointestinal Therapeutics Market By Drug Class, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 320 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
消化管治療薬市場：薬剤クラス別、用途別、流通チャネル別：世界の機会分析と産業予測、2023～2032年
出版日: 2023年08月01日
発行: Allied Market Research
ページ情報: 英文 320 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

消化管治療薬市場は、製薬部門からの消化管治療薬需要の増加により、2023年から2032年にかけて5.0％の大幅な成長率を記録する見込み-Allied Market ResearchAllied Market Researchの調査レポート「消化管治療薬市場」によると、消化管治療薬市場は2022年に395億米ドルと評価され、2023年から2032年にかけてCAGR 5％で成長し、2032年には645億米ドルに達すると予測されています。

消化管治療学は、消化管（GI）に影響を及ぼす疾患や状態の診断、治療、管理に焦点を当てた医学と医療の一分野を指します。消化管治療学には、胃食道逆流症（GERD）、炎症性腸疾患（IBD）、消化性潰瘍、下痢などのさまざまな消化管障害に対処することを目的とした、薬物療法、外科的介入、生活習慣の改善、食事の推奨など、さまざまな医学的アプローチが含まれます。この分野は、胃腸の健康問題を経験している人々の症状を緩和し、治癒を促進し、合併症を管理し、全体的な幸福を向上させることを目的としています。

Gastrointestinal Therapeutics Market-IMG1

消化器病学、免疫学、微生物学などの分野で進められている調査は、消化器疾患の根本的な原因やメカニズムをより深く理解することに貢献しています。この知識は、標的療法やより個別化された治療アプローチの開発につながります。胃腸治療薬市場は、胃食道逆流症（GERD）、炎症性腸疾患（IBD）、過敏性腸症候群（IBS）などの胃腸疾患の有病率の上昇により大きな成長を遂げています。例えば、2022年の米国生物工学情報センター（NCBI）によると、胃食道逆流症（GERD）は米国で最もよく診断される消化器疾患の一つであり、有病率は20％で、直接的および間接的なコストにおいて大きな経済的負担となっています。これらの疾患は世界中で数百万人に影響を及ぼしているため、効果的な治療オプションに対する需要が急増しており、市場成長の原動力となることが期待されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 消化器疾患の増加
      • 高齢者人口の増加
      • 製品上市数の増加
    • 抑制要因
      • バイオシミラーの承認に向けた政府の厳しい規制
      • 医薬品の特許切れ
    • 機会
      • 研究開発活動の活発化
      • 新興市場における成長機会

第4章 消化管治療薬市場：薬剤クラス別

  • 概要
  • 生物製剤
  • プロトンポンプ阻害薬
  • アミノサリチル酸塩
  • 制酸剤
  • 緩下剤
  • H2拮抗薬
  • その他

第5章 消化管治療薬市場：用途別

  • 概要
  • 炎症性腸疾患
    • 炎症性腸疾患の消化管治療薬市場：タイプ別
  • 胃食道逆流症
  • 消化性潰瘍疾患
    • 消化性潰瘍疾患の消化管治療薬市場：タイプ別
  • 過敏性腸症候群
  • その他

第6章 消化管治療薬市場：流通チャネル別

  • 概要
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第7章 消化管治療薬市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他

第8章 競争情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • AbbVie Inc.
  • AstraZeneca plc
  • Pfizer Inc.
  • Bayer AG
  • Bausch Health Companies Inc.
  • Takeda Pharmaceutical Company Limited
  • Cosmo Pharmaceuticals
  • Organon Group of Companies
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Limited
図表

LIST OF TABLES

  • TABLE 01. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. GASTROINTESTINAL THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GASTROINTESTINAL THERAPEUTICS MARKET FOR PROTON PUMP INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GASTROINTESTINAL THERAPEUTICS MARKET FOR AMINOSALICYLATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GASTROINTESTINAL THERAPEUTICS MARKET FOR ANTACIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GASTROINTESTINAL THERAPEUTICS MARKET FOR LAXATIVES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GASTROINTESTINAL THERAPEUTICS MARKET FOR H2 ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. GASTROINTESTINAL THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. GASTROINTESTINAL THERAPEUTICS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GASTROINTESTINAL THERAPEUTICS MARKET FOR PEPTIC ULCER DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DISEASE GASTROINTESTINAL THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. GASTROINTESTINAL THERAPEUTICS MARKET FOR IRRITABLE BOWEL SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. GASTROINTESTINAL THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GASTROINTESTINAL THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GASTROINTESTINAL THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 30. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. UK GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 68. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 74. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 80. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 83. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 84. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 87. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 93. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 94. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 99. ABBVIE INC.: KEY STRATERGIES
  • TABLE 100. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 101. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 102. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 103. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 104. ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 105. PFIZER INC.: KEY EXECUTIVES
  • TABLE 106. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 107. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 108. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 109. BAYER AG: KEY EXECUTIVES
  • TABLE 110. BAYER AG: COMPANY SNAPSHOT
  • TABLE 111. BAYER AG: PRODUCT SEGMENTS
  • TABLE 112. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 113. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
  • TABLE 114. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 115. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
  • TABLE 116. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 119. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 122. COSMO PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 123. COSMO PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 124. COSMO PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 125. COSMO PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 126. ORGANON GROUP OF COMPANIES: KEY EXECUTIVES
  • TABLE 127. ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT
  • TABLE 128. ORGANON GROUP OF COMPANIES: PRODUCT SEGMENTS
  • TABLE 129. ORGANON GROUP OF COMPANIES: PRODUCT PORTFOLIO
  • TABLE 130. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 131. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 132. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 133. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 134. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 137. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 138. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 139. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF GASTROINTESTINAL THERAPEUTICS MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN GASTROINTESTINAL THERAPEUTICS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS, 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR PROTON PUMP INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR AMINOSALICYLATES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR ANTACIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR LAXATIVES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR H2 ANTAGONISTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR PEPTIC ULCER DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR IRRITABLE BOWEL SYNDROME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. GASTROINTESTINAL THERAPEUTICS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 29. U.S. GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CANADA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. MEXICO GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. GERMANY GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. UK GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SPAIN GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF EUROPE GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. CHINA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. INDIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. AUSTRALIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH KOREA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. BRAZIL GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SAUDI ARABIA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA GASTROINTESTINAL THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: GASTROINTESTINAL THERAPEUTICS MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2022
  • FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 70. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 71. COSMO PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. ORGANON GROUP OF COMPANIES: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. ORGANON GROUP OF COMPANIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 75. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 76. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 77. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
目次
Product Code: A03195

The Gastrointestinal Therapeutics Market is likely to experience a significant growth rate of 5.0% from 2023-2032 owing to increase in demand for gastrointestinal drugs from pharmaceutical sector - Allied Market Research. According to a new report published by Allied Market Research, titled, "Gastrointestinal Therapeutics Market," The gastrointestinal therapeutics market was valued at $39.5 billion in 2022, and is estimated to reach $64.5 billion by 2032, growing at a CAGR of 5% from 2023 to 2032. Gastrointestinal therapeutics refers to the branch of medicine and healthcare focused on the diagnosis, treatment, and management of disorders and conditions affecting the gastrointestinal (GI) tract. Gastrointestinal therapeutics involves a range of medical approaches, including medications, surgical interventions, lifestyle modifications, and dietary recommendations, aimed at addressing various GI disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), peptic ulcers, diarrhea, and more. The field aims to alleviate symptoms, promote healing, manage complications, and improve overall well-being for individuals experiencing gastrointestinal health issues.

Gastrointestinal Therapeutics Market - IMG1

Ongoing research in fields such as gastroenterology, immunology, and microbiology contribute to a deeper understanding of the underlying causes and mechanisms of gastrointestinal disorders. This knowledge leads to the development of targeted therapies and more personalized treatment approaches. The gastrointestinal therapeutics market has experienced significant growth owing to the rise in prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). For instance, according to the National Center for Biotechnology and Information (NCBI) in 2022, gastroesophageal reflux disease (GERD) is one of the most commonly diagnosed digestive disorders in the U.S. with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs. As these disorders affect millions of people worldwide, there is a surge in demand for effective therapeutic options, which is expected to drive market growth.

In addition, the development of biologic therapies has revolutionized the treatment landscape for gastrointestinal disorders, which further supports the market growth. Biologics, such as monoclonal antibodies and cytokine inhibitors, provide targeted interventions that modify the inflammatory processes associated with disorders such as Crohn's disease and ulcerative colitis. Furthermore, ongoing research and development activities in the field of gastrointestinal therapeutics contribute toward the market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available gastrointestinal therapeutics. For instance, Inspirna, Inc. is conducting a phase 1 study of RGX-202-01 (Ompenaclid) as combination therapy in 2nd Line RAS mutant advanced colorectal cancer. Thus, a rise in ongoing research and development activities in the field of gastrointestinal therapeutics is expected to drive the market growth.

The gastrointestinal therapeutics market is segmented into drug class, application, distribution channel, and region. By drug class, the market is segregated into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn's disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. By distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Others).

Major key players that operate in the gastrointestinal therapeutics market are AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. Key players have adopted product launch, product approval, and clinical trial as key developmental strategies to improve the product portfolio of the gastrointestinal therapeutics market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastrointestinal therapeutics market analysis from 2022 to 2032 to identify the prevailing gastrointestinal therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gastrointestinal therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gastrointestinal therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • Biologics
  • Proton Pump Inhibitors
  • Aminosalicylates
  • Antacids
  • Laxatives
  • H2 Antagonists
  • Others

By Application

  • Inflammatory Bowel Disease
    • Type
    • Crohn's Disease
    • Ulcerative Colitis
  • Gastroesophageal Reflux Disease
  • Peptic Ulcer Disease
    • Type
    • Gastric Ulcer
    • Duodenal Ulcer
  • Irritable Bowel Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Bausch Health Companies Inc.
    • Cosmo Pharmaceuticals
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Limited
    • AbbVie Inc.
    • Organon Group of Companies
    • Pfizer Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of gastrointestinal diseases
      • 3.4.1.2. Rise in geriatric population
      • 3.4.1.3. Rise in number of product launches
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent government regulations toward approval of biosimilars
      • 3.4.2.2. Patent expiry of drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in R&D activities
      • 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Biologics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Proton Pump Inhibitors
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Aminosalicylates
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Antacids
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Laxatives
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. H2 Antagonists
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Inflammatory Bowel Disease
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Inflammatory Bowel Disease Gastrointestinal Therapeutics Market by Type
  • 5.3. Gastroesophageal Reflux Disease
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Peptic Ulcer Disease
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
    • 5.4.4. Peptic Ulcer Disease Gastrointestinal Therapeutics Market by Type
  • 5.5. Irritable Bowel Syndrome
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Others
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country

CHAPTER 6: GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Drug Class
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Drug Class
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Drug Class
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Drug Class
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Drug Class
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Drug Class
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Drug Class
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Drug Class
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Drug Class
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Drug Class
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Drug Class
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Drug Class
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Drug Class
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Drug Class
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Drug Class
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Drug Class
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Drug Class
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Drug Class
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Drug Class
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. AstraZeneca plc
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pfizer Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Bayer AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Bausch Health Companies Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Takeda Pharmaceutical Company Limited
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Cosmo Pharmaceuticals
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Organon Group of Companies
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Bristol-Myers Squibb Company
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Teva Pharmaceutical Industries Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments